QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trugman, J. M. Articles by Wooten, G. F. Search for Related Content PubMed PubMed Citation Articles by Trugman, J. M. Articles by Wooten, G. F.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 7, 2927-2935, Copyright © 1987 by Society for Neuroscience

ARTICLE

Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions

JM Trugman and GF Wooten

The relative roles of D1 and D2 dopamine receptor stimulation in mediating the antiparkinsonian effects of dopaminergic drugs remain unclear. To determine the functional metabolic consequences of selective dopamine receptor stimulation, we used 2-deoxyglucose (2-DG) autoradiography to examine the effects of the D1 agonist SKF-38393 and the D2 agonist LY-171555 on regional cerebral glucose utilization (RCGU) in rats with unilateral 6-hydroxydopamine (6-OHDA) substantia nigra lesions. SKF-38393 (0.5-25.0 mg/kg) and LY-171555 (0.01-5.0 mg/kg) produced indistinguishable behavioral responses, including vigorous contralateral rotation. Treatment with each drug similarly increased glucose utilization, dose-dependently, in the parafascicular thalamus, subthalamic nucleus, deep layers of the superior colliculus, and lateral midbrain reticular formation ipsilateral to the nigral lesion; glucose utilization was decreased in the ipsilateral lateral habenula. By contrast, the D1 and D2 agonists differentially altered glucose utilization in the entopeduncular nucleus (EP) and the substantia nigra pars reticulata (SNr). SKF-38393, 5.0 and 25.0 mg/kg, increased glucose utilization 127 and 275%, respectively, in the pars reticulata ipsilateral to the lesion. LY-171555, 1.0 and 5.0 mg/kg, caused maximal contralateral turning, yet did not alter glucose utilization in the ipsilateral SNr. The glucose utilization response of the ipsilateral EP paralleled that of the SNr demonstrating large increases following administration of SKF-38393 and minimal change following the use of LY-171555. The results demonstrate that the selective D1 agonist reproduces the marked glucose utilization increases (2-3-fold above control values) in the EP and SNr that were previously observed using L-DOPA and apomorphine in this model, whereas the selective D2 agonist does not.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J.-C. Corvol, M.-P. Muriel, E. Valjent, J. Feger, N. Hanoun, J.-A. Girault, E. C. Hirsch, and D. Herve Persistent Increase in Olfactory Type G-Protein {alpha} Subunit Levels May Underlie D1 Receptor Functional Hypersensitivity in Parkinson Disease J. Neurosci., August 4, 2004; 24(31): 7007 - 7014. [Abstract] [Full Text] [PDF]

				T. Hayakawa, M. C. J. Chang, S. I. Rapoport, and N. M. Appel Selective Dopamine Receptor Stimulation Differentially Affects [3H]Arachidonic Acid Incorporation, a Surrogate Marker for Phospholipase A2-Mediated Neurotransmitter Signal Transduction, in a Rodent Model of Parkinson's Disease J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1074 - 1084. [Abstract] [Full Text]

				K. J. Black, T. Hershey, M. H. Gado, and J. S. Perlmutter Dopamine D1 Agonist Activates Temporal Lobe Structures in Primates J Neurophysiol, July 1, 2000; 84(1): 549 - 557. [Abstract] [Full Text] [PDF]

				K. A. Keefe and A. C. Adams Differential Effects of N-Methyl-D-Aspartate Receptor Blockade on Eticlopride-Induced Immediate Early Gene Expression in the Medial and Lateral Striatum J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1076 - 1083. [Abstract] [Full Text]

				T. Hershey, K. J. Black, M. K. Stambuk, J. L. Carl, L. A. McGee-Minnich, and J. S. Perlmutter Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias PNAS, September 29, 1998; 95(20): 12016 - 12021. [Abstract] [Full Text] [PDF]

				D. S. Kreiss, C. W. Mastropietro, S. S. Rawji, and J. R. Walters The Response of Subthalamic Nucleus Neurons to Dopamine Receptor Stimulation in a Rodent Model of Parkinson's Disease J. Neurosci., September 1, 1997; 17(17): 6807 - 6819. [Abstract] [Full Text] [PDF]

				K. J. Black, M. H. Gado, and J. S. Perlmutter PET Measurement of Dopamine D2 Receptor-Mediated Changes in Striatopallidal Function J. Neurosci., May 1, 1997; 17(9): 3168 - 3177. [Abstract] [Full Text] [PDF]

				R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.-C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa PNAS, April 1, 1997; 94(7): 3363 - 3367. [Abstract] [Full Text] [PDF]

				C. Gerfen, T. Engber, L. Mahan, Z Susel, T. Chase, F. Monsma Jr, and D. Sibley D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science, December 7, 1990; 250(4986): 1429 - 1432. [Abstract] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help